Analysts See $-0.50 EPS for Flex Pharma, Inc. (FLKS)

April 17, 2018 - By Marie Mckinney

Flex Pharma, Inc. (NASDAQ:FLKS) Logo

Analysts expect Flex Pharma, Inc. (NASDAQ:FLKS) to report $-0.50 EPS on May, 2.They anticipate $0.01 EPS change or 2.04 % from last quarter’s $-0.49 EPS. After having $-0.46 EPS previously, Flex Pharma, Inc.’s analysts see 8.70 % EPS growth. The stock increased 2.31% or $0.126 during the last trading session, reaching $5.576. About 1,910 shares traded. Flex Pharma, Inc. (NASDAQ:FLKS) has risen 57.61% since April 17, 2017 and is uptrending. It has outperformed by 46.06% the S&P500.

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Coverage

Among 3 analysts covering Flex Pharma (NASDAQ:FLKS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Flex Pharma had 4 analyst reports since January 25, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, February 13 by Jefferies. On Friday, April 6 the stock rating was maintained by Jefferies with “Buy”. The firm earned “Buy” rating on Thursday, March 8 by H.C. Wainwright.

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company has market cap of $100.21 million. The firm operates through two divisions, Consumer Operations and Drug Development. It currently has negative earnings. The Company’s lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis.

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.